Copyright
©The Author(s) 2024.
World J Virol. Sep 25, 2024; 13(3): 95349
Published online Sep 25, 2024. doi: 10.5501/wjv.v13.i3.95349
Published online Sep 25, 2024. doi: 10.5501/wjv.v13.i3.95349
Table 4 Summary of current studies examining the use of vitamin D in coronavirus disease 2019 and other viral infections conditions
Ref. | n | Vitamin D type | Vitamin D dosage | Application method | Viral infection | Disease status | Results |
Entrenas Castillo et al[61], 2020 | 76 | Vitamin D3 (calcifediol) | 0.532 mg on day 1, then 0.266 mg on days 3 and 7, and weekly thereafter | Oral | SARS-CoV-2 | Mild–moderate | The need for intensive care and the mortality rate were lower in patients receiving vitamin D treatment |
Murai et al[62], 2021 | 240 | Vitamin D3 (cholecalciferol) | 200000 IU loading dose | Oral | SARS-CoV-2 | Mild–moderate | High-dose vitamin D treatment did not improve clinical outcomes of COVID-19 patients |
Rastogi et al[63], 2020 | 40 | Vitamin D3 (cholecalciferol) | 60000 IU/d for 7 d | Oral | SARS-CoV-2 | Light | Vitamin D treatment shortened the time to PCR negativity |
Maghbooli et al[64], 2020 | 235 | Vitamin D3 (cholecalciferol) | 50000 IU/wk | Oral | SARS-CoV-2 | Mild–moderate | Adequate vitamin D levels shortened hospitalizations and reduced rates of serious illness |
Annweiler et al[65], 2020 | 77 | Vitamin D3 (cholecalciferol) | 80000 IU single dose | Oral | SARS-CoV-2 | Moderate–severe | COVID-19-related mortality rates were lower in patients receiving vitamin D therapy |
Cangiano et al[66], 2020 | 90 | Vitamin D3 (cholecalciferol) | 25000 IU/mo | Oral | SARS-CoV-2 | Moderate–severe | Severity of COVID-19 symptoms decreased in older individuals with vitamin D deficiency |
Giannini et al[67], 2021 | 100 | Vitamin D3 (cholecalciferol) | 100000 IU/mo | Oral | SARS-CoV-2 | Mild–moderate | High doses of vitamin D were found to be effective in reducing complications due to COVID-19 |
Ling et al[68], 2020 | 50 | Vitamin D3 (cholecalciferol) | 400 IU/d | Oral | Respiratory tract infections | Mild–moderate | Vitamin D supplementation has been found effective in reducing the incidence of respiratory infections |
Tan et al[69], 2020 | 43 | Vitamin D3 (cholecalciferol) | 1000 IU/d | Oral | SARS-CoV-2 | Moderate–severe | Vitamin D supplementation was found to be effective in reducing hospital stay and complications |
- Citation: Engin MMN, Özdemir Ö. Role of vitamin D in COVID-19 and other viral infections. World J Virol 2024; 13(3): 95349
- URL: https://www.wjgnet.com/2220-3249/full/v13/i3/95349.htm
- DOI: https://dx.doi.org/10.5501/wjv.v13.i3.95349